



Scientific Program

Friday, May 17th 2024

10:00 -10:15 **Congress Opening**

10:15 - 12:30 **Plenary Session 1: Emerging trends in cancer-associated thrombosis (Part I)**

Chairs: *Benjamin Brenner (Haifa, Israel), Paolo Simioni (Padova, Italy)*

Endothelial cell dysfunction in cancer: a modulator of CAT and metastasis?

Jamie O'Sullivan (Dublin, Ireland)

Artificial Intelligence in CAT

Rushad Patell (Boston, USA)

The gut microbiome in cancer and thrombosis

Christoph Reinhardt (Mainz, Germany)

Stroke in patients with cancer

Deborah Siegal (Ottawa, Canada)

Selected Abstract

12:30 -13:30 **Debate: Do we need more complex and specific RAMs for CAT?**

Chairs: *Paolo Prandoni (Bologna, Italy), Mario Mandalà (Perugia, Italy)*

YES: *Andres Munoz-Martin (Madrid, Spain)*

NO: *Ingrid Pabinger (Vienna, Austria)*

13:30 – 14:30 Lunch Sessions

14:30 – 15:00 Coffee

15:00 – 17:15 **Plenary Session 2: Emerging trends in cancer-associated thrombosis (Part II)**

Chairs: *Laurent Bertoletti (Auvergne-Rhone-Alpes, France), Francesco Dentali (Varese, Italy)*

Trends and Updates on the Epidemiology of Cancer-Associated Thrombosis

Ang Li (Houston, USA)



Cancer immunotherapy in CAT

Claudine Graf (Mainz, Germany)

Bleeding and thrombosis during CAR-T therapy

Elena Rossi (Roma, Italy)

Location of metastasis and complications of anticoagulant treatment

Maria Barca-Hernando (Seville, Spain)

Selected Abstracts

17:15 - 17:45 Coffee Break

17:45 – 18:45 **Plenary Lecture: 8th Simon Karpatkin Memorial Lecture**

The Conference Chairs

Introduction to Lecture: *Alok A. Khorana (Cleveland, USA)*

VTE treatment in patients with cancer: Reflections on an evolving landscape

Agnes Y.Y. Lee (Vancouver, Canada)



Saturday, May 18th 2024

8:30 – 10:45 Plenary Session 3: Anticoagulation in hematological cancer patients

Chairs: *Roberto Santi (Alessandria, Italy), Giancarlo Castaman (Firenze, Italy)*

VTE and mortality in patients with hematological malignancies

Kristen Sanfilippo (St. Louis, MO, USA)

Management of CAT in thrombocytopenia: the uncertain balance between risks and benefits of platelet transfusion to support anticoagulation

Simon J. Stanworth (Oxford, UK)

Pharmacological approach to increase platelet count: from ITP to chemotherapy-induced thrombocytopenia

Monica Carpenedo (Milano, Italy)

Selected Abstracts

10:45 – 11:15 Coffee break

11:15 – 13:30 Plenary Session 4: Exploring the relationship between hemostasis and cancer:

New insights

Chairs: *Erica De Candia (Roma, Italy), Hugo ten Cate (Maastricht, The Netherlands)*

Platelets: A weapon against cancer

Paolo Gresele (Perugia, Italy)

FXa inhibitors in cancer progression

Andrea Alimonti (Bellinzona, Switzerland)

Coaguloma and tumor microenvironment

Janusz Rak (Montréal, Canada)

Crosstalk between NETs and tumor progression

Laurence Panicot-Dubois (Marseille, France)

Selected Abstracts

13:30 – 14:30 Lunch

14:30 – 15:00 Coffee



15:00 – 17:00 **Poster Discussion Sessions**

Poster Session 1: Biomarkers/Hypercoagulability I

Poster Session 2: Thrombohemorrhagic complications

Poster Session 3: Epidemiology

Poster Session 4: Thromboprophylaxis in cancer

Poster Session 5: Treatment of thrombosis in cancer

Poster Session 6: Hemostatic proteins and cancer biology

Poster Session 7: Therapeutic challenges

Poster Session 8: Biomarkers/Hypercoagulability II

17:00 – 18:15 **Interactive session: Spotlight on prevention of VTE in cancer patients**

Chair: *Ajay K. Kakkar (London, UK)*

A case of thrombosis in medical patient

Walter Ageno (Varese, Italy)

A case of thrombosis in surgical patient

Giancarlo Agnelli (Perugia, Italy)

A case of thrombosis during anti-cancer drug treatment

Marina Elena Cazzaniga (Monza, Italy)

Discussant: *Anna Falanga (Bergamo, Italy)*

18:15 – 19:00 **Special "Noble" Session**

Chairs: *Anna Falanga (Bergamo, Italy), Caterina Rizzi (Bergamo, Italy)*

Patient and Public Involvement in CAT Research: Necessary or glorified tokenism?

Simon Noble (Cardiff, UK)



Sunday, May 19th 2024

8:30 – 10:15 Plenary Session 5: Past, present, and future of CAT - A Round Table Discussion

Chairs: *Elvira Grandone (Foggia, Italy), Alok A. Khorana (Cleveland, USA)*

New drugs, old problems: Immune checkpoint inhibitors and CAT

Alok A. Khorana (Cleveland, USA)

Real-world Outcomes Data for DOAC vs LMWH vs other Anticoagulants: Promises and Pitfalls

Nicole Kuderer (Washington, USA)

FXI inhibitors: a new option for the prevention and treatment of cancer-associated thrombosis

Marcello Di Nisio (Chieti, Italy)

General Discussion

10:15 – 11.45 Plenary session 6: Novel biomarkers for predicting clinical outcomes in cancer patients

Chairs: *Marina Marchetti (Bergamo, Italy), Andrea Remuzzi (Bergamo, Italy)*

Proteomics prediction of CAT and mechanistic insights

Jeffrey Zwicker (New York, USA)

Age-related clonal hemopoiesis and thrombosis

Liran I. Shlush (Tel Aviv, Israel)

Machine Learning for the prediction of CAT

Simon Mantha (New York, USA)

Selected Abstracts

11:45 - 12:45 *Lunch*

12:45 – 14:35 Plenary Session 7: Anticoagulation in cancer patients

Chairs: *Anna Falanga (Bergamo, Italy), Roberto Labianca (Bergamo, Italy)*

Risk of recurrent VTE in cancer patients after discontinuation of anticoagulant therapy

Gary E Raskob (Oklahoma, USA)

Extended antithrombotic prophylaxis after cancer surgery

Cecilia Becattini (Perugia, Italy)



Trends in the management of pediatric and adolescent patients with cancer-associated VTE

Gili Kenet (Tel Aviv, Israel)

Selected Abstracts

14:35 – 14:40 **Concluding Remarks**

N.B: I soci AIOM avranno diritto ad uno sconto del 10% sulla quota “Full Registration” (La Quota Registrazione Soci AIOM sarà pari a 720,00€ iva inclusa)